Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658007 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
A Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01658007 is a Early Phase 1 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 3 participants.
The verdict
NCT01658007, a Early Phase 1 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators want to learn about treating relapsed/refractory lymphoblastic leukemia and lymphoma with a drug called sirolimus. The investigators are using sirolimus along with other cancer drugs that are often given to patients with relapsed leukemia and lymphoma. The main purpose of this study is to determine if sirolimus can be given safely in combination with standard drugs used to treat relapsed lymphoblastic leukemia/lymphoma.
Interventions
- DRUG Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658007
The ClinicalTrials.gov registry entry for NCT01658007 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.
NCT01658007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01658007 about?
NCT01658007 is a clinical study titled "Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma". The investigators want to learn about treating relapsed/refractory lymphoblastic leukemia and lymphoma with a drug called sirolimus. The investigators are using sirolimus along with other cancer drugs that are often given to patients with relapsed leukemia and lymphoma. The main purpose of this stu...
What is the current status of trial NCT01658007?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2012-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01658007?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT01658007?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.